Effects of L-Carnitine supplement on plasma coagulation and anticoagulation factors in hemodialysis patients

REFERENCES

• Jungers P, Khoa TN, Massy ZA, Incidence of atherosclerotic arterial occlusive accidents in predialysis and dialysis patient: A multicentric study in the Ile de France district. Nephrol Dial Transplant. 1999;14:898–902.
   PubMed Web of Science ®Google Scholar
• Stenvinkel P. Inflammation in end-stage renal failure: Could it be treated? Nephrol Dial Transplant. 2002;17(Suppl. 8):33–38.
   PubMed Web of Science ®Google Scholar
• Ambuhl PM, Wuthrich RP, Korte W, Schmid L, Krapf R. Plasma hypercoagulability in hemodialysis patients: Impact of dialysis and anticoagulation. Nephrol Dial Transplant. 1997;12:2355–2364.
   PubMedGoogle Scholar
• Smits JHM, Liden J, Blankestijn PJ, Rabelink TJ. Coagulation and hemodialysis access thrombosis. Nephrol Dial Transplant. 2002;15:1755–1760.
   Google Scholar
• Song IS, Yang WS, Kim SB, Lee JH, Kwon TW, Park JS. Association of plasma fibrinogen concentration with vascular access failure in hemodialysis patients. Nephrol Dial Transplant. 1999;14:1137–1141.
   Google Scholar
• Vaziri ND, Gonzales EC, Wang J, Said S. Blood coagulation, fibrinolytic, and inhibitory proteins in end-stage renal disease: Effect of hemodialysis. Am J Kidney Dis. 1994;23:828–835.
   PubMed Web of Science ®Google Scholar
• Oda H, Ohno M, Ohashi H. Coagulation and fibrinolysis factors in dialysis patients with and without ischemic heart disease. Adv Perit Dial. 2000;16:152–155.
   PubMedGoogle Scholar
• Segarra A, Chacon P, Martinez-Eyarre C, Circulating levels of plasminogen activator inhibitor type-1, tissue plasminogen activator, and thrombomodulin in hemodialysis patients: Biochemical correlations and role as independent predictors of coronary artery stenosis. J Am Soc Nephrol. 2001;12:1255–1263.
   PubMedGoogle Scholar
• Lottermoser K, Petras S, Poge U, The fibrinolytic system in chronic renal failure. Eur J Med Res. 2001;6:372–376.
   PubMedGoogle Scholar
• Molino D, De Santo NG, Marotta R, Anastasio P, Mosavat M, De Lucia D. Plasma levels of plasminogen activator inhibitor type 1, factor VIII, prothrombin activation fragment 1+2, anticardiolipin, and antiprothrombin antibodies are risk factors for thrombosis in hemodialysis patients. Semin Nephrol. 2004;24:495–501.
   PubMedGoogle Scholar
• Trimarchi H, Duboscq C, Genoud V, Plasminogen activator inhibitor-1 activity and 4G/5G polymorphism in hemodialysis. J Vasc Access. 2008;9:142–147.
   PubMedGoogle Scholar
• Deguchi K, Izumi K, Noguchi M, Coagulation and fibrinolysis in patients with chronic renal failure on maintenance hemodialysis (abstr). Nippon Ketsueki Gakkai Zasshi. 1989;52:140–146.
   PubMedGoogle Scholar
• Vaziri ND, Toohey J, Paule P, Alikhani S, Hung E. Coagulation abnormalities in patients with end-stage renal disease treated with hemodialysis. Int J Artif Organs. 1984;7:323–326.
   PubMedGoogle Scholar
• Uchida Y. Long-term hemodialysis and changes in variables of coagulation and fibrinolysis (abstr). Fukuoka Igaku Zasshi. 1991;82:576–585.
   PubMedGoogle Scholar
• Erdem Y, Haznedaroglu IC, Celik L, Coagulation, fibrinolysis and fibrinolysis inhibitors in hemodialysis patients: Contribution of arteriovenous fistula. Nephrol Dial Transplant. 1996;11:1299–1305.
   PubMedGoogle Scholar
• Pola P, De Martini D, Gerardino L, De Rossi S, Tondi P. The action of propionyl-L-carnitine on the vasal endothelium: Increased t-PA synthesis and a decrease in the activity of PAI-1. A preliminary study. Drugs Exp Clin Res. 1992; 18:343–348.
   PubMedGoogle Scholar
• Daugirdas JT, Stone JCV. Physiologic principles and urea kinetic modeling. In: Daugirdas JT, Blake PG, Ing TS, eds. Handbook of Dialysis. 3rd ed., Philadelphia: Lippincott Williams & Wilkins; 2001:15–45.
   Google Scholar
• Evans A. Dialysis-related carnitine disorder and levocarnitine pharmacology. Am J Kidney Dis. 2003;41(Suppl. 4):S13–S26.
   PubMedGoogle Scholar
• Alberty R, Albertyova D. Biological variation of free and total carnitine in serum of healthy subjects. Clin Chem. 1997;43:2441–2443.
   PubMedGoogle Scholar
• Guarnieri G, Biolo G, Vinci P, Massolino B, Barazzoni R. Advances in carnitine in chronic uremia. J Ren Nutr. 2007;17:23–29.
   PubMedGoogle Scholar
• Elisaf M, Bairaktari E, Katopodis K, Effect of L-carnitine supplementation on lipid parameters in hemodialysis patients. Am J Nephrol. 1998;18:416–421.
   PubMedGoogle Scholar
• Guarnieri GF, Ranieri F, Toigo G, Lipid lowering effect of carnitine in chronically uremic patients treated with maintenance hemodialysis. Am J Clin Nutr. 1980;33:1489–1492.
   PubMed Web of Science ®Google Scholar
• Libby P, Simon DI. Inflammation and thrombosis. Circulation. 2001;103:1718–1720.
   PubMed Web of Science ®Google Scholar
• Savica V, Santoro D, Mazzaglia G, L-carnitine infusions may suppress serum C-reactive protein and improve nutritional status in maintenance hemodialysis patients. J Ren Nutr. 2005;15:225–230.
   PubMed Web of Science ®Google Scholar
• Duranay M, Akay H, Yilmaz FM, Senes M, Tekeli N, Yücel D. Effects of L-carnitine infusions on inflammatory and nutritional markers in hemodialysis patients. Nephrol Dial Transplant. 2006;21:3211–3214.
   PubMed Web of Science ®Google Scholar
• Danesh J, Lewington S, Thompson SG, Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: An individual participant meta-analysis. J Am Med Assoc. 2005;294:1799–1809.
   PubMed Web of Science ®Google Scholar
• Undas A, Kolarz M, Kopec G, Tracz W. Altered fibrin clot properties in patients on long-term hemodialysis: Relation to cardiovascular mortality. Nephrol Dial Transplant. 2008;23: 2010–2015.
   PubMed Web of Science ®Google Scholar